agree @Cguv
yield numbers on PL6 will most likely require improvement providing process data for any acquirer
proving die cost per wafer is the right commercial number - if it only achieves commercial number parity on current lines and processes it will be difficult to justify on a buyer perspective - (10% or better is considered commercially viable )
so those yield numbers are foundational to a successful market place outcome
@Sparky68
my take is IMEC will need to be part of the sale / partnership process as they fab the cell - atm GF run the wafer and imec lay it up - any acquirer or partner interested in the cell will need technology transfer to foundry and a demonstration run to verify process and outcome - reproducibility - and successful qualification
if that occurs and is successful at 20nm a premium transaction is possible
anything short of that and a premium is at risk imo
just a few thoughts on the fly and could well be wrong - glah
- Forums
- ASX - By Stock
- 4DS
- 4DS - Anything but Charting
4DS
4ds memory limited
Add to My Watchlist
4.17%
!
2.5¢

4DS - Anything but Charting, page-32468
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
2.5¢ |
Change
0.001(4.17%) |
Mkt cap ! $51.52M |
Open | High | Low | Value | Volume |
2.4¢ | 2.7¢ | 2.4¢ | $157.6K | 6.231M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 683428 | 2.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.6¢ | 1823042 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 683428 | 0.025 |
28 | 3804392 | 0.024 |
21 | 7126947 | 0.023 |
12 | 6861480 | 0.022 |
13 | 1092095 | 0.021 |
Price($) | Vol. | No. |
---|---|---|
0.026 | 1803042 | 8 |
0.027 | 1813867 | 7 |
0.028 | 430000 | 2 |
0.029 | 427592 | 5 |
0.030 | 547908 | 8 |
Last trade - 16.11pm 27/06/2025 (20 minute delay) ? |
Featured News
4DS (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online